192 results about "Hp - Helicobacter pylori" patented technology

A breath test for diagnosing the presence of Helicobacter pylori in a subject is described. The method of diagnosing Helicobacter pylori is performed as follows. First, a safe and effective amount of urea, preferably appropriately labelled, is administered to the subject. Second, a plurality of the exhaled breaths of the subject is analyzed to detect the concentration of a cleavage product or products, produced when urease cleaves the substrate. The measured concentrations are then fitted to a curve, and the derivative is then calculated, to indicate the presence or absence of Helicobacter pylori infection in the subject.

PCT No. PCT / SE95 / 01212 Sec. 371 Date May 29, 1997 Sec. 102(e) Date May 29, 1997 PCT Filed Oct. 17, 1995 PCT Pub. No. WO96 / 14091 PCT Pub. Date May 17, 1996A preparation for administering isotope-labelled urea together with acid in a solid form that is influenced by activity of Helicobacter pylori in the stomach only, avoiding any non-Helicobacter (unspecific) urease activity in the oral cavity and the pharynx. The preparation dissolves very quickly in the stomach. The preparation is used to show increased urease activity in the stomach in association with an ongoing Helicobacter pylori infection.

The invention relates to lactobacillus CN2018, CGMCC No. 4286 and application thereof. The lactobacillus CN2018 has acid resistance, has an effect of suppressing growth of helicobacter pylori (H. pylori SS1 for instance) and urease activity, has a stronger effect of suppressing the adherence of helicobacter pylori to human gastric epithelial cells SGC7901, and has an effect of preventing or relieving infection degree of mice infection of the helicobacter pylori.

A rapid, non-invasive breath-test method and device for diagnosing the presence or absence of H. pylori in a subject without administration of isotopic tracers is described. The device consists of a highly sensitive colorimetric ammonia sensor placed in contact with sampled subject breath. The sensor is measured using appropriate reflection spectroscopy instrumentation. The breath-test method consists of measuring a basal ammonia level with the device, administering non-isotopic urea and continuing measurement of the ammonia content in a plurality of consecutive breaths. Diagnostic differences in breath ammonia are identified between H. pylori infected and uninfected individuals.

The invention discloses a method for building a helicobacter pylori nucleic acid fingerprint spectrum, which comprises PCR (polymerase chain reaction) amplification, SAP (severe acute pancreatitis) enzymatic digestion, transcription and nuclease digestion, purification, mass spectrometer detection and the like. A helicobacter pylori nucleic acid fingerprint spectrum database is set up on the basis of the method. According to the generated mass peak spectrum of the experiment, the helicobacter pylori of a sample to be detected can be quickly identified, so the method can be widely applied in the fields of helicobacter pylori types and classification, environmental sanitation, public safety qunarantine and the like.

The present invention is an orally-administrable composition for preventing and treating Helicobacter pylori-associated stomach gastritis and ulcers, and for preventing Helicobacter pylori-associated stomach cancer. The invention is a herb or herb extract containing an anti-H. pylori activity. The invention further includes methods for making and methods for using the invention.

The present invention provides one kind of genetic engineering multivalent subunit vaccine for preventing and treating human helicobacter pylori infection and its preparation process. The vaccine consists of active helicobacter pylori UreB fragment UreB414 as the central antigen component, other combined protective antigens, and intramolecular or extramolecular adjuvant. Compared with univalent vaccine, the multivalent combined vaccine can stimulate the body to generate more powerful and more comprehensive helicobacter pylori resisting specific immune reaction.

The strain of micro-organism Lactobacillus fermentum ME-3 is a novel anti-microbial and anti-oxidative probiotic. It has a high anti-microbial effect on Escherichia coli, Shigella sonnei, Staphylococcus aureus, Salmonella typhimurium, and moderate activity against Helicobacter pylori strains. The strain of micro-organism possesses Mn-superoxide dismutase and both its lysates and intact cells have high anti-oxidative activity, increasing the glutathione red-ox ratio in blood sera and able to capture toxic hydroxyl radicals. The strain of micro-organism could be used as a probiotic for the production of functional food (yoghurt, cheese) and non-comestibles (tablets, capsules) for the prophylaxis of intestinal and uroinfections, both for the prevention and treatment of chronic diseases, caused by prolonged oxidative stress.

The invention relates to a recombinant fusion protein vaccine and an attenuated live vector vaccine for treating and preventing helicobacter pylori (Hp) infection, and belongs to the field of biopharmaceutics. The recombinant fusion protein vaccine and the attenuated live vector vaccine for expressing the recombinant fusion protein are characterized in that: the recombinant fusion protein is formed by connecting immune protective function fragments of helicobacter pylori cytotoxin relevant gene protein CagA from helicobacter pylori, vacuolization cytotoxin VacA and urease subunit UreB linearly, and the immunogenicity and immune protection of the recombinant fusion protein are verified through animal experiments. The live vaccine has the advantages that: 1, an Hp fusion protein gene can beexpressed stably; 2, mucosa and systemic immune response can be induced after immunity; and 3, the method is convenient, the cost is low, and the economic benefit is obvious. Therefore, the attenuated live vector vaccine can be used as candidate vaccines for treating and preventing the Hp infection.

Live strains of Lactobacillus acidophilus HY2177 and Lactobacillus casei HY2743 maintained in nutritious foods, such as yogurt, imbue them with prophylactic and / or therapeutic properties. Such foods are beneficial in the prevention and / or treatment of gastritis, duodenal and gastric ulcers caused by infection from Helicobacter pylori (also referred to as H. pylori). The properties of these bacteria are boosted by the addition of egg yolk containing antibodies specific to H. pylori antigen derived from "fractionated H. pylori" and may be administered as active strains alone in a food supplement, or the active strains may be combined with H. pylori-antibodies (IgY).

The invention relates to a composition for the treatment and / or prevention of infection by gastrointestinal pathogens, in particular Helicobacter pylori and / or a disease associated with infection by said gastrointestinal pathogen in mammals.

The invention discloses an urea enzyme epitope fuse peptiolipid plastid vaccine to against pylorus bolt bacteria infection, which is characterized by the following: choosing fuse peptide of pylorus bolt bacteria urea enzyme B subunit and stick film adjuvant cholera morbus toxin B subunit as immunogen; coating the immunogen with liposome; producing the liposome vaccine. This liposome vaccine can evoke organism to generate special immune response and inhibit planting of pylorus bolt bacteria in stomach.

The invention discloses a compound probiotic functional food capable of inhibiting helicobacter pylori. The compound probiotic functional food capable of inhibiting helicobacter pylori comprises 20-40parts of prebiotics, 20-30 parts of bacillus bifidus flora, 10-20 parts of bacillus acidophilus, 5-10 parts of lactobacillus casei, 5-10 parts of lactobacillus reuteri, 3-8 parts of lactobacillus paracasei, 3-8 parts of lactobacillus gasseri and 5-10 parts of lactobacillus rhamnosus. A preparation method of the compound probiotic functional food capable of inhibiting helicobacter pylori comprisesthe following steps: performing pretreatment on raw materials, namely putting weighed raw materials into a dry mixer so as to be subjected to uniform mixing; putting the mixed materials into a tabletmachine and performing tablet compression so as to obtain tablets, or directly weighing and bagging the mixed materials; and then, carrying out laboratory testing, and warehousing qualified productsso as to obtain finished products. The compound probiotic functional food capable of inhibiting helicobacter pylori solves the problem of existing functional foods, namely insufficient inhibition on helicobacter pylori production and spread of helicobacter pylori due to lack of variety of bacterial flora and unscientific proportion.

The invention relates to a composition for the treatment and / or prevention of infection by gastrointestinal pathogens, in particular Helicobacter pylori and / or a disease associated with infection by said gastrointestinal pathogen in mammals.

A kit for quickly determining infection of polyloric spirillum consists of kit body, application reagent prepared from distilled water and 1% of urase solution, plastic reaction plate with round scrobicula on its surface and Huatemen test paper prepared by soaking said paper completely in 1% of urea solution and in phenol red indicator then drying it in the air.

The invention provides a composition for resisting helicobacter pylori and an application of the composition. Each 100g of the composition comprises the following active components according to the content: 5-20g of inactivated lactobacillus reuteri, 0.1-1g of inactivated lactobacillus paracasei, 1.5-25g of bifidobacterium animalis viable bacteria, 1.2-20g of lactobacillus rhamnosus, 5-10g of hippophae rhamnoides fruit powder, 0.1-1g of a broccoli seed aqueous extract, 20-30g of fructo-oligosaccharide and 10-70g of lacitiol. According to the composition, the inactivated lactobacillus reuteri,the inactivated lactobacillus paracasei, the hippophae rhamnoides fruit powder, the broccoli seed aqueous extract, the fructo-oligosaccharide and the lacitiol are prepared into a specific compositionformula together, and the formula not only can well prevent and treat bacterial infection of gastrointestinal tracts and bacterial infection of oral cavities, particularly concurrently has better mouth feel flavor, and is green and healthy due to no addition of seasonings of essence and the like.

The invention discloses a helicobacter pylori urease B antigenic epitope polypeptide and application thereof. The amino acid sequence of the antigenic epitope polypeptide is the sequence 37 in a sequence table, and the encoding gene sequence of the antigenic epitope polypeptide is the sequence 28 in the sequence table. The antigenic epitope polypeptide can stimulate organisms to generate helicobacter pylori resistant protective immune response so as to enhance the suppression of the helicobacter pylori infection, improve the capacity of removing germs of the organisms, and play a promoting role in development of corresponding vaccines, research on pathogenic mechanism, and clinical diagnosis.

The invention provides a kit, application of the kit in detection of pepsinogen I, pepsinogen II, a helicobacter pylori antibody and gastrin 17 and a method for detecting the pepsinogen I, the pepsinogen II, the helicobacter pylori antibody and the gastrin 17 by using the kit. The kit comprises a first coating film and a second coating film, wherein at least one region in the first coating film is coated with a fluorescent microsphere-labeled pepsinogen I antibody, a fluorescent microsphere-labeled pepsinogen II antibody, a first fluorescent microsphere-labeled helicobacter pylori antigen and a fluorescent microsphere-labeled gastrin 17 antibody; the second coating film comprises a first region, a second region, a third region, a fourth region and a fifth region which are separated; a formed fluorescent microsphere material comprises a polystyrene-methyl methacrylate copolymer. The kit and the method which are provided by the invention have the advantages of high sensitivity, high specificity, quickness, simplicity, capability of realizing objective measurement and the like.

A novel blood group antigen binding (BAB) adhesin protein was isolated and purified, whereby said protein or fractions thereof bind specifically to Helicobacter pylori fucosylated blood group antibodies. Said adhesin has a molecular weight of about 73.5 kDa and the N-terminal sequence for the adhesin and the corresponding DNA show homologies between different strains of H. pylori. Said adhesin and / or DNA is useful for diagnose and therapy and / or profylax directed against H. pylori induced infections, e.g. gastritis and acid peptic disease.

The invention relates to a biological engineering detection product and an application of the gene chip, and in particular relates to a detection gene chip for helicobacter pylori infection individualized treatment. The chip is capable of simultaneously detecting polymorphisms of helicobacter pylori clarithromycin medicine-resistant mutation sites A2142G and A2143G, carbostyril medicine-resistant mutation sites Asn87(N87K) and Asp91(D91G / Y / N), and sites 2C19*2(G6981A) and 2C19*3(G636A) related to metabolism of a proton pump inhibitor on human cytochrome enzyme CYP450. The chip detection method disclosed by the invention is rapid and accurate and is capable of identifying helicobacter pylori etiology, carrying out medicine-resistant analysis of clarithromycin and carbostyril, and analyzing metabolic individual differences of the proton pump inhibitor, so that the detection gene chip is used for guiding individualized administration of helicobacter pylori infection triplex process treatment.

There are described a simple examination method of infection with Helicobacter pylori possibly presenting in a gastric mucosa, and a device therefor. The examination is conducted by collecting gas in gastric cavity, and measuring mainly ammonia and additionally organic amines which are generated due to activities of the bacilli. The measurement is carried out by leading the gas in gastric cavity into oral cavity by vomiting-reflex, and sucking the gas by a metering suction pump through a gas detection tube to read-out a length of color-changed area in the gas detection tube.

The present invention relates to a method for treating a Helicobacter pylori (IP) infection and / or an associated disease in an individual, comprising administering to the individual a therapeutically effective amount of a pharmaceutical composition containing a short-chain fatty acid or a pharmaceutically acceptable salt thereof, alone or in combination with an anti-HP agent, and a pharmaceutically acceptable carrier, wherein the short-chain fatty acid has the formula: in which R1 and R2, independently, are C1-C8alkyl or H, R3 is aryl or heteroaryl, and n is 0, 1, 2, 3, 4, 5 or 6. The present invention also relates to a method for treatment of Helicobacter pylori (HP) infection or disease associated with HP infection by administering a therapeutically effective amount of an HDAC inhibitor or a pharmaceutically acceptable salt thereof, alone or in combination with an anti-HP agent, and a pharmaceutically acceptable carrier.

A method for the in vivo detection of urease-producing helicobacter in the upper stomach is disclosed. The dense carrier is divided into two separate groups which are combined with separate reagent indicators, one of which also contains urea. The carriers are food soluble products, preferably sugar beads having a diameter of approximately 0.2 to 3.0 mm. The treated carriers and urea are encapsulated in a soluble capsule which is administered to a patient. The density of the carriers cause the capsule to migrate to the gastric mucosa, where the capsule, but not the reagents, is dissolved, placing the reagents and urea in direct contact with the gastric mucosa. The urea reacts with any urease present in the stomach by creating ammonia, which increases the pH in the immediate vicinity of the urea containing carrier and indicator beads. The two reagents react differently, through color change, to the increase in pH, which is viewed through use of an endoscope. A preferred first reagent is bromothymol blue (dibromothymolsulfonphthalein), which changes yellow in the presence of urease, and a preferred second reagent is phenol red (phenolsulfonphthalein), which turns red in the presence of urease.

Strains of Lactobacillus which have been selected for their capability of reducing gastrointestinal inflammation, such as that due to Helicobacter pylori, and products derived from these strains, including agents for treatment or prophylaxis of inflammation associated with Helicobacter pylori for administration to humans and include conditioned media in which the selected strains have grown and protein-containing extracts of the conditioned media.

The invention provides three Th cell epitope peptide and code DNA of pylorus spirillum urease B subunit, also providing a bacterin of B cell epitope which contains the triepitope peptide and an additional urease B subunit. Among them, the epitope peptide is the polypeptide which has one of the amino acid residue sequences as follows: 1) hasing amino acid sequence of sequence 2, sequence3 and sequence 7 in sequence table; 2) replacing, deleting or appending the amino acid sequence of sequence 2, sequence3 and sequence 7 in sequence table by one or several amino acid residue to form derivanting polypeptide. The coded DNA is one of the following sequences: 1) hasing the ribonucleotide sequence of sequence 8, sequence 9 and sequence sequence 10 table. 2) Hasing the ribonucleotide sequence of same coded product with sequence 8, sequence 9 and sequence10 in sequence table. The epitope vaccine which contains the polypeptide of this invention has the protein vaccine of amino acid sequence in sequence 12 of sequence table. The vaccine or medication which is made by using the polypeptide of the invention as active component can clean out the infection caused by pylorus spirillum and has wide application prospect in medical realm.

The invention discloses a helicobacter pylori urease B antigen epitope polypeptide and application thereof. The amino acid sequence of the antigen epitope polypeptide is the sequence 34 in a sequence table, and the coding gene sequence of the antigen epitope polypeptide is the sequence 25 in the sequence table. The antigen epitope polypeptide provided by the invention can stimulate an organism togenerate helicobacter pylori resistance protective immunity reaction, thereby enhancing the effect of inhibiting helicobacter pylori infection, improving germ eliminating capacity of the organism, and playing an improving role in corresponding researches on development of vaccine and pathogenic mechanism and clinical diagnosis.

The invention relates to a toothpaste capable of inhibiting and killing helicobacter pylori, and relates to the technical field of toothpaste. The toothpaste is prepared from the following componentsin parts by weight: 5 to 10 parts of bacteria inhibiting powder, 20 to 35 parts of water, 15 to 30 parts of humectant, 10 to 17 parts of thickener, 2 to 4 parts of adhesive, 3 to 8 parts of foaming agent, 20 to 35 parts of friction agent, 2 to 4 parts of sweetener, 1 to 5 parts of preservative, 3 to 7 parts of corrosion inhibitor, and 1 to 7 parts of aromatic. The invention also provides a preparation method of the toothpaste. The prepared toothpaste has the advantages that the helicobacter pylori in an oral cavity can be inhibited and killed; the better inhibiting effect is realized on multiple types of aerobic and anaerobic bacteria in the oral cavity; the breezing of harmful bacteria in the oral cavity is prevented; the microecological balance of the oral cavity is adjusted; the toothpaste is a good traditional Chinese medicine toothpaste with health-care and preventing functions for the oral cavity; the market prospect is broad.

A preparation method of an anti Helicobacter pylori active antibacterial peptide gastric mucosa nanoparticle delivery system. Helicobacter pylori is highly sensitive to the antibacterial peptide and does not generate resistance to the antibacterial peptide, and the antibacterial peptide nanoparticles have short acting time on Helicobacter pylori. Compared with an antibacterial peptide suspension, the antibacterial peptide nanoparticles stay a long time in the gastric mucosa, are not easy to be damaged by gastric acid and protease, and have very strong gastric mucous layer permeability to increase the concentration of antimicrobial peptides in the gastric mucosa, and are conducive to inhibit and kill planting Helicobacter pylori in the gastric mucosa. The antibacterial peptide nanoparticles have the function of eliminating Helicobacter pylori infection under lower amount of drug. The invention provides a novel approach and dosage form for the treatment of Helicobacter pylori.

The invention relates to Helicobacter pylori antigen HLA restrictive immunodominance epitope peptide as well as a preparation method and application thereof. The dominance epitope peptide has the amino acid sequences shown in SEQ ID NO:63, 74, 95 and 105. The invention also provides a preparation method of the epitope peptide, and further provides application of the epitope peptide to preparation for preventing or treating Helicobacter pylori infection.